|
May 19
|
Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade
|
|
May 15
|
Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space
|
|
May 14
|
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights
|
|
Sep 3
|
Nkarta to Participate in Upcoming Investor Conference
|
|
Aug 14
|
Why Nkarta Stock Is Soaring Today
|
|
Aug 14
|
Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
|
|
Aug 13
|
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
|
|
Jul 24
|
Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus
|
|
Jun 27
|
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
|
|
May 11
|
Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans
|
|
May 10
|
Nkarta Inc (NKTX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Analysis
|
|
May 9
|
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
|
|
May 7
|
Opportunity Alert: 3 Undiscovered Stocks About to Explode on Wall Street’s Radar
|
|
Apr 3
|
Nkarta to Participate in Upcoming Investor Conferences
|
|
Mar 25
|
Why Nkarta Stock Just Boomeranged Following A Massive Dive On Friday
|
|
Mar 25
|
Nkarta Announces Pricing of $240 Million Underwritten Offering
|
|
Mar 23
|
Nkarta Inc (NKTX) Posts Full Year 2023 Financial Results: A Focus on NKX019 and Pipeline Realignment
|
|
Mar 22
|
Why Top 1% Biotech Stock Nkarta Just Plummeted, Undercutting Its 50-Day Line
|
|
Mar 21
|
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
|
|
Mar 19
|
3 Overlooked Stocks Ready to Capture the Market by Storm
|